Early Career Investigator Award - Past Awardees

2024 Awardees

• Nathan Bennett, AbbVie
• Janine Tom, Amgen
• Jason Shields, AstraZeneca
• Meredith Eno, Blueprint Medicines, Inc.
• Yichen Tan, Bristol Myers Squibb
• Rebecca Green, Bristol Myers Squibb
• Anne-Catherine Bédard, Dow
• Nicholas White, Genentech
• Linda Suen-Lai, GlaxoSmithKline
• Stephen Murphy, Johnson & Johnson
• Nadine Kuhl, Merck & Co., Inc.
• David Candito, Merck & Co., Inc.
• Matthew Winston, Merck & Co., Inc. (+BMS)
• Lauren Holder, Novartis
• Rebecca Gallego, Pfizer
• Adam Brown, Pfizer
• Thomas Knauber, Pfizer
• Alan Cherney, Sanofi (Amgen/Vertex)

2023 Awardees

• Nicholas Babij, Corteva Agriscience.
• Gregg Barcan, GSK.
• Souvagya Biswas, Dow Chemical.
• Artiom Cernijenko, Novartis Institutes for BioMedical Research.
• Michael Clift, AbbVie.
• John Curto, Pfizer.
• Abdellatif El Marrouni, Merck.
• Gary Gallego, Pfizer.
• Melissa Grenier-Davies, GSK.
• Valer Jeso, GSK.
• Brian Laforteza, Janssen.
• Stephen Lathrop, AbbVie.
• Toma Levin, Biogen.
• Emma McInturff, Pfizer.
• Manish Mishra, PPG Industries.
• Leslie Ofori, Novartis Institutes for BioMedical Research.
• Yam Poudel, BMS.
• Kyle Quasdorf, Amgen.
• Hong Ren, Merck.
• Thomas Scattolin, Mirati Therapeutics.
• Paige Stout, Janssen.
• Shuwen Sun, Merck.
• Jack Terrett, Genentech.
• Ngoc Duc Tran, Janssen.
• Miao Yu, BMS.
• Ping Zhang, Novartis Institutes for BioMedical Research.
• Susan Zultanski, Merck.

2022 Awardees

• Simone Bonazzi, Novartis. “Discovery and characterization of a first-in-class selective IKZF2 glue degrader for immuno-oncology applications”
• Yining Ji Chen, Merck. “Insight from mechanistic studies informs better processes”
• Emily Cherney, BMS. “Exploring pathways in immuno-oncology: Discovery of IDO1 inhibitors and STING agonists”
• Andrew DeAngelis, FMC. “Novel heterocyclic amides for the control of plant parasitic nematodes”
• Maryll Geherty, BMS. “Innovative approaches in process chemistry: The synthesis and multikilogram manufacture of complex pharmaceutical agents”
• Kaid Harper, AbbVie. “Photochemistry and Electrochemistry at Commercial Scale”
• Martin Himmelbauer, Biogen. “Design and optimization of potent, selective and brain penetrant apoptosis signal-regulating kinase 1 (ASK1) inhibitors”
• Allen Hong, Genetech. “Stereocontrolled Synthesis of Arylomycin-Based Gram-Negative Antibiotic GDC-5338”
• Terry Lebold, Janssen. “Discovery of selective and brain penetrant Casein Kinase 1 (CK1) Delta inhibitors for the treatment of circadian rhythm disorders”
• Hasnain Malik, Novartis. “Identification and Optimization of Novel Cystic Fibrosis Transmembrane Conductance Regulator Correctors”
• Connor Martin, Janssen. “Discovery of Pyrazolecarboxamide RORγt Inverse Agonists at Janssen”
• Eric Phillips, . “Process Research and Development at Merck: Collaborative and Cohesive Work Across Multiple Phases and Modalities”
• John Roberts, Merck. “Towards a New Direct Process: Synthesis of Methylmethoxysilanes from Dimethyl Carbonate and Pentacopper Silicide”
• Janelle Sauvageau, Dow. “My glyco-chemistry journey within the National Research Council of Canada”
• Daniel Schmitt, Pfizer. “Parallel Synthesis of α-Branched Amines”
• Austin Smith, Loxo – Lilly. “Development and manufacture of oncology drug candidates with high molecule complexity”
• David Thaisrivongs, Merck. “Synthetic macrocyclic peptides that target protein-protein interactions: the discovery and early chemistry development of a PCSK9 inhibitor”
• Carolyn Wei, Amgen. “Leveraging High-Throughput Experimentation to Enable a Differentiated Pipeline”

2021 Awardees

• Omar Ahmad, Blueprint. “Development of next generation calicheamicin ADCs”
• Christophe Allais, Pfizer. “Process development and optimization to manufacture an active pharmaceutical ingredient”
• Matthew Beaver, Amgen. “Role of continuous manufacturing to advance Amgen’s synthetic portfolio”
• Raphaelle Berger, Merck. “Discovery of MK-6158 an oral, once daily, soluble guanylate cyclase (sGC) stimulator for the treatment of pulmonary arterial hypertension”
• Alexander Buitrago-Santanilla, GSK. “Development of a Nanoscale Chemistry Direct-to-Biology (D2B) Platform”
• Anne-Marie Dechert Schmitt, Pfizer. “Use of synthetic organic chemistry to impact medicinal chemistry project delivery”
• Amelie Dion, Merck/Pfizer. “An outsider path to process chemistry”
• Anna Dunn, GSK. “Rapid kinetics workflow: Incorporating high-throughput experimentation, machine learning, graphical analysis, and fit-for-purpose modeling into accessible tools for accelerated drug development”
• Candice Joe, BMS. “Development of a Negishi cross coupling process”
• Anais Jolit, AbbVie. “Switching on the blue light in the pharmaceutical industry: Implementation of a global platform for metallophotoredox chemistry at AbbVie”
• Leo Joyce, Arrowhead. “Enabling organic synthesis through the development and application of novel analytical methods”
• Carolyn Leverett, Pfizer. “Design and synthesis of novel tubulysin payloads and site-specific antibody drug conjugates overcoming in-vivo acetate liability”
• Xiaoli Liao, AbbVie. “Selective reduction of proteins for site-specific antibody-drug conjugation”
• Brian Loy, Corteva Agriscience. “Unique picolinamides for fungal disease control”
• Yu Lu, Lilly. “Decarboxylative borylation approach for the synthesis of chiral cyclopropane”
• Feng Peng, Merck. “Accelerating drug discovery and development through Innovation in green chemistry”
• Vivek Rauniyar, Novartis. “Drugging ERK and RAF nodes of MAP kinase pathway.”
• Chris Regens, Gilead. “Toward a cure for chronic hepatitis B: The development of Selgantolimod (GS-9688)”
• Troy Reynolds, AbbVie. “Process development of an RORγt inverse agonist”
• Trevor Sherwood, BMS. “Optimization of indole-based antagonists of toll-like receptors 7 and 8 (TLR7/8) through C-2 variations”
• Steven Silverman, Merck. “Invention of an ideal synthesis of molnupiravir enabled by protein engineering”
• Lauren Sirois, Genentech. “Next-generation process chemistry: Striving for better, faster, smarter development of stereoselective cross-coupling reactions toward pharmaceutical targets”
• Craig Stivala, Genentech. “Discovery of a chiral amphiphilic iridium catalyst for carbon-heteroatom bond formation: Reactions of amines, anilines, indoles, and other various nucleophiles”
• Shun Su, BMS. “Biphenyl acid and aryl hydroxypyrimidinone derivatives as APJ receptor agonists”
• Benjamin Taft, Novartis. “Discovery of clinical candidate INE963: A potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cure in uncomplicated malaria”
• Dan Treitler, BMS. “Design and development of the commercial process to Deucravacitinib”
• Tom Willumstad, Dow. “Investigating a silane modified polymer (SMP) based coating formulation”

2020 Awardees

• Matthew Belowich, Dow. “Lewis Acids as Highly Active Silanol Polycondensation Catalysts Affording Low Levels of Cyclosiloxanes”
• Tamas Benkovics, Merck. “Innovation for the Synthesis of Diverse Nucleosides”
• Nick Desrosiers, Pfizer. “Development of Difluoromethylation Methodologies for Large-Scale Processes”
• Anna Fryszkowska, Merck. “Biocatalysis in the pharmaceutical industry – chemistry for tomorrow’s earth.”
• Chong Han, Genentech. “Chemoselective, Stereocontrolled Cu-Catalyzed C-N Couplings Towards a Highly Potent mPI3Ka Inhibitor GDC-0077”
• Sebastien Monfette, Pfizer. “Nickel catalysis: Novel ligands and reactions of practical importance to the pharmaceutical industry”
• Ryan Moslin, BMS. “Inhibition of TYK2 via the Pseudokinase: The Discovery of Deucravacitinib”
• Jaclyn Murphy, DuPont. “Development of new materials for electronic applications”
• Zack Oblak Oblak, GSK. “The design and development of a manufacturing process for GSK’772”
• Martins Oderinde, BMS. “Photocatalytic [2+2] Cycloaddition for Building Cyclobutane-Fused Three-Dimensional Molecular Complexity”
• Andrew Parsons, Amgen. “Development of a commercial manufacturing process for an atropisomeric KRAS G12C inhibitor”
• Ryan Patman, Pfizer. “Design and Synthesis of Carbonucleoside Inhibitors of PRMT5 for the Treatment of Cancer: A Desymmetrization Approach”
• David Pearson, Dow. “Carbon-carbon centered radical initiators for polymerization of unsaturated monomers.”
• Christopher Plummer, Merck. “Identification and Optimization of Positive Allosteric GPR40 Agonists for Diabetes”
• Danica Rankic, Pfizer. “Strategies toward robust and scalable syntheses of α-pyrazolyl pyrrolidines”
• Mari Rosen, Dow. “Chromium Catalysts with Phospholane Ligands for Ethylene Tetramerization”
• Janelle Steves, GSK. “HTE in 3D: Implication of phosphine featurization methods on HTE design and analysis of reaction outcomes”
• Aimee Usera, Novartis. “Ride of a lifetime: a novel half-life extension technology succeeding across chemical space”
• Jason Zbieg, Genentech. “Discovery of a Chiral Amphiphilic Iridium Catalyst for Carbon- Heteroatom Bond Formation: Reactions of Amines, Anilines, Indoles and Other Various Nucleophiles.”

2019 Awardees

• Brad Bailey, Dow. “Polyolefin catalysts for the production of ethylene-based fluids”
• Bryan Barton, Dow Dupont E&I. “Shifting the oxidation pathways of polyethylene to provide carbonaceous species in high yield”
• Amanda Dombrowski, Abbvie. “High-throughput reaction screening enabled by small scale solid dispensing”
• Shuzhi Dong, Merck. “Discovery of MK-8153: ROMK inhibitor as new mechanism diuretic for hypertension and heart failure”
• Stephen Greszler, Abbvie. “Impacting the pipeline through discovery synthesis groups: Cystic fibrosis, HCV, and immunology”
• Michael Harris, NovoNordisk. “Development of PMC friendly approaches to the construction of synthetically challenging cyclopropane motifs”
• Josh Kaitz, Dupont. “Rational design of organic materials for advanced microlithography”
• Jonrock Kong, Merck. “Design and development of catalytic processes for the synthesis of antiviral agents EFdA (MK-8591) and vaniprevir (MK-7009)”
• Chad Lewis, Pfizer. “Asymmetric atropisoinduction”
• David Marcoux, BMS. “Rationally designed, conformationally constrained inverse agonists of ROR?t: Identification of a potent, selective series with biologic-like in vivo efficacy”
• Tricia May-Dracka, Biogen. “Investigation of small molecule inhibitors of PLD for the treatment of ALS”
• Meredith McGowan, Merck. “Discovery and evolution of potent and selective heme-displacing IDO1 inhibitors”
• Jordan Meier, NCI. “New insights into acetylation & oncometabolism from chemoproteomics”
• Theo Michels, eFfector. “Synthesis of bioactive flavagline analogues as inhibitors of cap-dependent translation: Discovery of eFT226”
• Erik Regalado, Merck. “Universal chromatographic methods and fit for purpose workflows in the research and development of new pharmaceuticals”
• Benjamin Sherry, Merck. “Process development in the pharmaceutical industry”
• Iulia Strambeau, GSK. “Convergent synthesis of the NS5B inhibitor GSK8175 enabled by transition metal catalysis”
• Jenna Terebetski. “Want to improve your (bio)performance? Take a closer look at the physical properties”
• Rubben Torella, Pfizer. “Designing for bias: Computational methods to drive rational design of G-protein biased agonists”
• Joseph Tucker, Pfizer. “High-throughput experimentation in flow: From screening to compound production”
• Steven Wisniewski, Bristol-Myers Squibb. “Robust catalytic transformations: Value of mechanistic studies in process chemistry”
• Robert Wright, Dow. “Organic molecules as forensic fuel markers”
• Ian Young, Genentech. “Application of under-utilized transformations to the synthesis of pharmaceutically relevant molecules”

2018 Awardees

• Karla Bravo-Altamirano, Corteva Agriscience. “Synthesis and bioactivity of carbohydrate-based macrocyclic picolinamide fungicides.”
• Alison Brewer, Pfizer. “Design, development and scale-up of a homogeneous Chan-Lam coupling”
• Matthew Campbell, Merck. “Herbicidal 2-aryl-1,2,3-triazoles”
• Benoit Cardinal-David, Abbvie. “Flow chemistry: Impact on early process development”
• Chiol Chung, Genentech. “Expedient synthesis of chiral tryptamines via a regioselective indole alkylation”
• Jamie McCabe Dunn, Merck. “Vignettes in process chemistry spanning enabling discovery chemistry to manufacturing route development”
• Marie Gabrielle-Braun, Genentech. “Discovery of GDC-0077: A highly selective inhibitor of PI3K-alpha that induces degradation of mutant-p110 alpha protein”
• Tom Greshock, Merck. “Innovative chemistry enabling drug discovery: Leveraging new frontiers in organic synthesis to improve success rate”
• David Laitar, Dow. “Boron- and copper-based TADF emitters: Synthesis, photochemical characterization and OLED device performance”
• Ricardo Lira, Pfizer. “Preparation and optimization of macrocyclic peptide-like inhibitors for intravenous applications”
• Sheng Liu, Dow. “Design and synthesis of high carbon content polymers via catalytic oxidative cross-coupling reactions for application in advanced manufacture”
• Michael Luzung, Bristol–Myers Squibb. “Discovering innovative and impactful chemistry through external collaborations”
• Steven M. Mennen, Amgen. “Integration of discovery and process development to deliver a high complexity BACE inhibitor”
• Joseph Pero, GlaxoSmithKline. “Discovery of a novel class of TRPV4 antagonists and optimization with respect to LLE, oral PK properties and off-target activity”
• Angela Puchlopek-Dermenci, Pfizer. “Commercial route development of a SMO inhibitor”
• Aaron Smith, Pfizer. “Speed to clinic: The critical role of organic synthesis in medicinal chemistry.”

2017 Awardees

• Scott Bader, Pfizer. “Synthesis of active pharmaceutical ingredients (APIs): Difficulties in the synthesis of the parts can be greater than that of the whole”
• Douglas Behenna, Pfizer. “Discovery and early enablement of PF-06747775: A next generation irreversible inhibitor of mutant EGFR for the treatment of NSCLC.”
• Aaron Burns, Dart Neuroscience. “Aldehyde Oxidase Metabolism in Drug Discovery”
• Vincent Chan, AbbVie. “Development of a robust process for Venetoclax”
• Michael Demartino, GlaxoSmithKline. “Next generation RET kinase inhibitor: Improved physicochemical and PK properties enhance local GI tissue distribution”
• Kevin Hesp, Pfizer. “Synthesis of Photoreactive Chemical Probes through Late-Stage Heterocyclic C-H Functionalization of Unmodified Biologically Active Molecules”
• Xin Linghu, Genentech. “Development of a practical synthesis of small molecule intermediate for THIOMAB-antibiotic conjugates (TACs) “
• Zhijian Liu, Merck. “Asymmetric Hydrogen Bonding Catalysis for the Synthesis of Dihydroquinazoline-containing Antiviral, Letermovir”
• Ana Minatti, Amgen. “Fueling the Alzheimer’s BACE1 Race with Genetic Insights and Cyclopropyloxazine BACE1 Inhibitors”
• Christian Nilewski, eFFECTOR Therapies. “Design and synthesis of novel natural product-inspired eIF4A inhibitors”
• Thomas Pillow, Genentech. “New Chemistries for Antibody-Drug Conjugates”
• Izzat Raheem, Merck. “Discovery of 2-pyridinone aminals: A prodrug strategy to advance a second generation of HIV-1 integrase strand transfer inhibitors”
• Matthew Schiffler, Lilly. “mPGES-1 Inhibitors from start to clinic”
• Eric Simmons, Bristol–Myers Squibb. “Discovery, Development and Mechanistic Study of Catalytic Transformations for the Multi-Kilogram Scale Synthesis of Pharmaceutical Intermediates”
• Emile Velthuisen, GlaxoSmithKline. “Design of Highly Potent Allosteric Integrase Inhibitors”
• Abbas Walji, Merck. “New opportunities for synthetic chemistry to enable drug discovery: Discovery of [18F]MK-6240 a novel PET imaging agent for tau pathology”

2016 Awardees

• Robert Aversa, Novartis. “ATR inhibitors for cancer: SBDD and mitigation of TDI “
• Haiming Zhang, Genentech. “Practical processes to selective estrogen receptor degrader GDC-0810 “
• Michael Schmidt, Bristol-Myers Squibb. “Case studies in process research: Small molecules with big challenges “
• Hua Xu, Pfizer. “Applications of sulfonyl fluorides in drug discovery and chemical biology”
• Erin P. Keaney, Novartis. “Disruption of autophagy in vivo via selective Vps34 inhibitors “
• Eric C. Hansen, Pfizer. “Mining pharmaceutical libraries for new ligands in nickel catalysis “
• Philip Fontaine, Dow Chemical. “Discovery and development of molecular polyolefin catalysts “
• Hilary S. Eidam, GlaxoSmithKline. “RET inhibitors for the treatment of irritable bowel syndrome “
• Christopher am Ende, Pfizer. “Design and application of photoaffinity probes to investigate the mechanism of action of ?-secretase inhibitors and modulators”
• Joseph R. Martinelli, Eli Lilly. “Evolution of a platform for aerobic processes”
• Malliga R. Iyer, National Institute on Alcohol Abuse and Alcoholism (NIAAA). “Synthetic approaches toward the design of multi-target compounds for the treatment of metabolic disorders and fibrosis “
• Anna V. Davis, Dow Chemical. “Advances in the direct control of polyethylene oxide molecular weight”
• Mirlinda Biba, Merck. “Chromatographic analysis and separation of short RNA oligonucleotides with novel liquid chromatography methods “
• Dennie S. Welch, AbbVie. “Development of a practical asymmetric synthesis of a TRPV1 antagonist “
• Arjun Raghuraman, Dow Chemical. “Sequential DMC/FAB-catalyzed alkoxylation towards high primary hydroxyl, high equivalent weight polyether polyols “
• Jackie Milne, Amgen. “Development of a robust process for a cMet inhibitor”

2015 Awardees

• Gregg Keaney, H3 Biomedicine. “Total synthesis of 6-deoxypladienolide D and assessment of splicing inhibitory activity in a mutant SF3B1 cancer cell line”
• Roy Helmy, Merck. “Development and implementation of innovative high-throughput screening and analysis solutions to support discovery and development of active pharmaceutical ingredients in the pharmaceutical industry”
• Patricia Brieva, L’Oreal. “Organic acid applications within the cosmeceutical industry “chemical peels””
• Reema Thalji, GlaxoSmithKline. “Structure-guided design and optimization of fluoroquinolone-substituted bacterial type IIA DNA topoisomerase inhibitors”
• Paul LaBeaume, Dow Chemical. “Application of synthetic organic chemistry in the design of cationic initiators for next generation photoresists”
• Kevin Cole, Eli Lilly. “Continuous processing: Chemical route development and GMP implementation”
• Timothy Briggs, Ensemble Therapeutics. “DNA-programmed chemistry toward macrocycle libraries for drug discovery”
• Andrew Vetter, Eastman Chemical. “Cobalt catalyzed reductive carbonylation of methanol”
• Andrew Hejl, Dow Chemical. “Designed hybridization – acrylic-epoxy hybrid dispersions for industrial coating applications”
• Nathan Ide, Pfizer. “Development of a commercial manufacturing process for Ibrance® (palbociclib)”
• Jeffrey Kallemeyn, AbbVie. “Approaches to the heterocyclic core of Ilorasertib”
• Andrew Satterfield, DuPont. “Carbonyl containing heterocycles as aromatic isosteres in 4-hydroxyphenylpyruvate dioxygenase (HPPD) herbicides”
• Antonella Converso, Merck. “Discovery of adenosine analog inhibitors of S-adenosylhomocysteine hydrolase”
• Ke Chen, Bristol-Myers-Squibb. “Overcoming steric and electronic obstacles: Development of efficient syntheses of active pharmaceutical ingredients”
• Martin Schnermann, National Cancer Institute. “Near-IR uncaging chemistry: Discovery and applications”
• Sheng Cui, Amgen. “Chiral chemistry for API synthesis”

2014 Awardees

• Nicole Knight, Dow Chemical. “Multidisciplinary problem solving in industrial research”
• Anthony A Estrada, Genentech. “Access to potent, selective, efficacious, and highly functionalized pyrimidoaminotropane mTOR inhibitors through the development of a flexible pyrimidine methodology”
• Christoph W Zapf, Pfizer. “Lessons learned from targeting interleukin-2 inducible T cell kinase (ITK) by a covalent approach”
• Kelly M George, L’Oreal. “Development of new skin care cleansing formulations using design of experiment and fast formulation tools”
• Beth M. Cooper, Dow Chemical. “Latex-pigment interactions in paint to reduce environmental impact and improve performance”
• Rebecca T Ruck, Merck. “MK-7655: Surprising synthetic complexity for seemingly straightforward steps”
• Adrian Ortiz, Bristol-Myers-Squibb. “Discovery of an innovative stereoselective synthesis of BMS-986001: A nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection”
• Sébastien Lemaire, Janssen Pharmaceutica. “Stereoselective C-glycosylation reactions with arylzinc reagents”
• Shashank Shekhar, AbbVie. “Discovery of novel catalytic technologies in the process development of HCV polymerase inhibitors”
• Jared L. Piper, Eli Lilly. “Process development and synthetic approaches for a CB1 inverse agonist”

2013 Awardees

• Santhosh F Neelamkavil, Merck. “Discovery of bridged bicyclic piperidines as GPR119 agonists for the treatment of Type 2 diabetes”
• Kurt Hirsekorn, Dow Chemical. “Selective methane activation and chlorocarbon development for climate friendly refrigerants via free radical chemistries”
• John S. Schneekloth, National Cancer Institute. “Chemical probes of protein sumoylation: Strategies and tactics”
• David L. Gray, Pfizer. “Medicinal chemistry at the blood-brain interface: Challenge and opportunity”
• Shawn D. Walker, Amgen. “Development of new methods for the asymmetric synthesis of small molecule drug candidates”
• Allyn T. Londregan, Pfizer. “Synthetic enablement for drug discovery: A new method for the addition of nucleophiles to pyridine-N-oxides”
• Owendi Ongayi, Dow Electronic Materials. “Development of materials for semiconductor device fabrication”
• Rami Hannoush, Genentech. “Peptides tools for targeting the zymogen form of a caspase”
• Artis Klapars, Merck. “Asymmetric synthesis of complex drug targets”

2012 Awardees

• Michael T. Rudd, Merck. “Discovery of vaniprevir (MK-7009) and MK-5172: Macrocyclic HCV NS3/4a protease inhibitors”
• Stephen M. Lynch, Hoffmann-La Roche. “Design and synthesis of novel monoamine triple reuptake inhibitors”
• Jason S. Tedrow, Amgen. “Route selection toward AMG 222: A direct tetrazole addition strategy toward building molecular complexity”
• Ming Xu, DuPont Crop Protection. “Synthesis and crop protection utility of novel fused heterobicyclic isoxazolines”
• Ed Cleator, Merck. “Discovery of an asymmetric synthesis of suvorexant”
• Lori Krim Gavrin, Pfizer. “Adventures in medicinal chemistry: Drug design and probe design”

2011 Awardees

• Vincent Mascitti, Pfizer. “Discovery of clinical candidate PF-04971729: An anti-diabetic agent from the structurally unique dioxa-bicyclo[3.2.1]octane class of SGLT2 inhibitors”
• Lisa A. Marcaurelle, Broad Institute. “Diversity-oriented synthesis: From macrocyclesto spirocycles and beyond”
• Brian C. Shook, Johnson & Johnson. “Indenopyrimidines as dual adenosine A2A/A1 antagonists for the treatment of Parkinson’s disease”
• Xing Dai, Merck. “Example of drug discovery program leading to the development of novel reactions”
• Aaron T. Wright, Pacific Northwest National Laboratory. “Identification of proteins relevant to bioenergy and disease pathology by chemical proteome profiling”
• Spencer D. Dreher, Merck. “Collaboration and communication in chemistry”
• Ted W. Johnson, Pfizer. “HIV integrase and the Golden Triangle: Overcoming synthetic challenges to compounds occupying unique chemical space”
• Martin D. Eastgate, Bristol-Myers Squibb. “On the palladium catalyzed oxidation of cyclic dienes”

2010 Awardees

• Vassil I. Elitzin, GlaxoSmithKline. “Efficient and practical synthesis of GSK812397, an HIV drug candidate”
• Qinhua Huang, Pfizer. “Synthesis and evaluation of NO donor containing carbonic anhydrase inhibitors”
• Andrew W. Fraley, Ensemble Discovery. “DNA-programmed chemistry approaches to macrocyclic lead compounds”
• Catherine A Faler, ExxonMobil Chemical Company. “Synthesis of pyridyl amine ligands for catalyzed ethylene oligomerization”
• Robert D. Mazzola, Jr., Merck/Ligand Pharmaceuticals. “Design and synthesis of novel ß-secretase (BACE) inhibitors”
• Hannah Yu, Eli Lilly. “Development of an efficient palladium-catalyzed intramolecular carbometalation reaction for the synthesis of a dibenzoxapine-containing tetrasubstituted exocyclic alkene”
• Fa Liu, National Cancer Institute. “Peptide mimetics disrupting protein-protein interactions discovered by post-solid phase modifications”
• Francis Gosselin, Merck. “Asymmetric hydrogenation of unprotected N-H ketoimines”
• Nidhi Gupta, Biodesign Institute, Arizona State University. “Synthetic ligands (synbodies): Syntheticalternatives to antibodies”
• Matthew M. Bio, Amgen. “Practial arene metallation chemistry”

2009 Awardees

• Craig J. Thomas, National Institutes of Health. “Bioactive small molecule discovery at the NIH chemical genomics center”
• David Tellers, Merck. “Application of automation to synthetic organic challenges Shawn M. Dirk, Sandia National Laboratories
  Development of novel polymeric capacitor dielectric materials”
• Xianhai Huang, Schering-Plough Research Institute. “Total synthesis and SAR development of potent antitumor natural product psymberin/irciniastatin A”
• Andrew E. Taggi, DuPont Crop Protection. “Chemistry at the interface of agriculture and medicine: Pyrazinones as tubulin modulators”
• Dafydd R. Owen, Pfizer. “Enabling the hit to lead process at Pfizer: The value of organic synthesis”
• M. Uljana Mayer, Pacific Northwest National Laboratory. “New probes for proteomics: Synthesis and application to problems in health and bioenergy”
• Karin M. Balss, Cordis Corporation. “Investigation of chemical spatial distribution of drug and polymer in drug-eluting stent coatings”
• Stefan G. Koenig, Sepracor. “Lessons learned: Development of a catalytic asymmetric hydrogenation process”
• Daniel H. Appella, National Institutes of Health. “Molecular designs for peptide nucleic acids in detection and multivalent platforms”
• Eric Assen B. Kantchev, Forma Therapeutics Singapore. “Rational exploration and exploitation of palladacycle diversity: Design and development of the SingaCycle family of NHC-palladacycle cross-coupling catalysts”
• Oliver Thiel, Amgen. “Synthesis and process development of an advanced drug candidate”
• Jeffrey C. Gildersleeve, National Cancer Institute. “Multidimensional carbohydrate microarrays for cancer research”

2008 Awardees

• Yue-Mei Zhang, Johnson & Johnson. “Regioselective Pd-catalyzed coupling of halopyrimidines and synthesis of functionalized pyrimidoindole heterocycles”
• Shane W. Krska, Merck. “Harnessing the power of high-throughput experimentation for catalytic reaction development at Merck”
• Percy H. Carter, Bristol-Myers Squibb. “Discovery of potent, selective, and orally bioavailable antagonists of CC Chemokine Receptor 2”
• Florence Mehlmann, Arkema. “Developments of new polymer architectures by controlled radical polymerization”
• Zhao-Kui Wan, Wyeth Research. “Serendipitous synthetic discoveries: A tale of phosphonium and oxybenzotriazole chemistry”
• Daniel Steiger, General Electric Global Research. “Rational design of surfaces with nanometer-sized domains for improved blood compatibility”
• Kanth V. B. Josyula, Aldrich Chemical Company. “Enabling boron-based reagents in chemical synthesis: A story of advancing science through new product development at Aldrich”
• Brian A. Johns, GlaxoSmithKline. “Novel synthetic methods to facilitate the pursuit of antiviral drugs”
• Erik J. Hembre, Eli Lilly. “Discovery of the NK-1 antagonist LY686017”

2007 Awardees

• J. Kent Barbay, Johnson & Johnson. “Synthesis and evaluation of small molecule C5a receptor antagonists”
• Kevin R. Campos, Merck. “Enantioselective arylation of N-Boc pyrrolidine”
• Robert M. Borzilleri, Bristol-Myers Squibb. “From cytotoxic agents to targeted therapies: A new era in oncology research”
• Robert A. Singer, Pfizer. “Development of nonproprietary catalysts for the palladium-catalyzed amination reaction”
• Edmund I. Graziani, Wyeth Research. “Synthesis and chemical biology of ILS-920: A novel non-immunosuppressive rapamycin analog with efficacy in multiple animal models of ischemic stroke